A Phase 1, Randomized, Open-Label, Single-Dose, 6-Period Crossover Study to Evaluate the Pharmacokinetics of BIIB091 Formulations and the Effect of Food in Healthy Participants
Latest Information Update: 05 Nov 2024
At a glance
- Drugs BIIB 091 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen
- 01 Nov 2024 Planned End Date changed from 4 Dec 2024 to 7 Dec 2024.
- 01 Nov 2024 Planned primary completion date changed from 4 Dec 2024 to 7 Dec 2024.
- 01 Nov 2024 Status changed from not yet recruiting to recruiting.